VWD diagnostic approaches
| VWD diagnostic strategy . | |
|---|---|
| Clinical phenotype | Increasing use of quantitative bleeding assessment tools; eg, ISTH-BAT |
| Hemostasis laboratory | • VWF:Ag |
| phenotype | • VWF:RCo: possibility of substituting a direct GPIb-binding assay |
| • VWF:CB combination of collagens I and III | |
| • VWF:F8 | |
| • VWFpp: aids in identification of accelerated clearance variants | |
| • VWF multimer profile | |
| • Ristocetin-induced platelet agglutination (RIPA) | |
| Genotype | • Type 1 VWD: premature for routine use, may be helpful in the future |
| • Type 2A: not usually needed | |
| • Type 2B: helpful confirmation and rules out PT-VWD | |
| • Type 2M: sometimes helpful | |
| • Type 2N: definitive differentiation from mild hemophilia A | |
| • Type 3: very helpful for genetic counseling | |
| VWD diagnostic strategy . | |
|---|---|
| Clinical phenotype | Increasing use of quantitative bleeding assessment tools; eg, ISTH-BAT |
| Hemostasis laboratory | • VWF:Ag |
| phenotype | • VWF:RCo: possibility of substituting a direct GPIb-binding assay |
| • VWF:CB combination of collagens I and III | |
| • VWF:F8 | |
| • VWFpp: aids in identification of accelerated clearance variants | |
| • VWF multimer profile | |
| • Ristocetin-induced platelet agglutination (RIPA) | |
| Genotype | • Type 1 VWD: premature for routine use, may be helpful in the future |
| • Type 2A: not usually needed | |
| • Type 2B: helpful confirmation and rules out PT-VWD | |
| • Type 2M: sometimes helpful | |
| • Type 2N: definitive differentiation from mild hemophilia A | |
| • Type 3: very helpful for genetic counseling | |
VWFpp indicates VWF propeptide; and PT-VWD, platelet-type VWD.